Antituberculous agent

This page covers all Antituberculous agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Enoyl-ACP reductase (InhA), InhA (enoyl-ACP reductase), Enoyl-ACP reductase (InhA), Catalase-peroxidase (KatG).

Targets

Enoyl-ACP reductase (InhA) · InhA (enoyl-ACP reductase) · Enoyl-ACP reductase (InhA), Catalase-peroxidase (KatG) · Arabinosyl transferases (EmbA, EmbB, EmbC) · Pantothenate synthetase (PanC); pyrazinamidase activation required

Marketed (2)

• Isoniazid (Rifinah) · National Taiwan University Hospital · Infectious Disease
  Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.
• Isoniazid (INH) · National Institutes of Health Clinical Center (CC) · Infectious Disease
  Isoniazid inhibits mycobacterial cell wall synthesis by interfering with mycolic acid production, thereby killing Mycobacterium tuberculosis.

Phase 3 pipeline (3)

• Isoniazid for 9 months · National Taiwan University Hospital · Infectious Disease
  Isoniazid inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, which is essential for Mycobacterium tuberculosis survival.
• Ethambutol Oral Product · Wits Health Consortium (Pty) Ltd · Infectious Disease
  Ethambutol inhibits mycobacterial arabinosyl transferases, disrupting the synthesis of the mycobacterial cell wall component arabinogalactan.
• Pyrazinamide Oral Product · Wits Health Consortium (Pty) Ltd · Infectious Disease
  Pyrazinamide is converted to pyrazinoic acid in mycobacteria, which disrupts bacterial cell wall synthesis and energy metabolism, leading to mycobacterial cell death.